The Health Ministry declared the viper venom serum production as a national project, and fully financed its NIS 20 million cost.
Kamada Ltd. (TASE: KMDA) has begun regular production of its new viper venom serum for Israel's Ministry of Health. Production will take place at Kamada's plant at Beit Kama in the Negev.
The Ministry of Health declared the viper venom serum production as a national project, and fully financed its NIS 20 million cost. Production has begun after the ministry certified the plant and its employees.
Kamada's share price rose 1.2% in morning trading to NIS 22.11, giving a market cap of NIS 601 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 30, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011